Teva beats analysts with $1.1b Q3 profit - Globes
Teva: This One Is Difficult (NYSE:TEVA) | Seeking Alpha
![TEVA- PHARMACEUTICAL INDUSTRIES LTD TEVA- PHARMACEUTICAL INDUSTRIES LTD Meeting Date: 07/13/2017 Country: - [PDF Document]](https://cdn.cupdf.com/img/1200x630/reader022/reader/2020062010/5ebef1f83bd3553b5b1d8e49/r-1.jpg "TEVA- PHARMACEUTICAL INDUSTRIES LTD TEVA- PHARMACEUTICAL INDUSTRIES LTD Meeting Date: 07/13/2017 Country: - [PDF Document]")
TEVA- PHARMACEUTICAL INDUSTRIES LTD TEVA- PHARMACEUTICAL INDUSTRIES LTD Meeting Date: 07/13/2017 Country: - [PDF Document]
Form 10-K
Why Teva Stock Could Be the Next General Electric Stock | InvestorPlace
Teva board OKs $3 billion stock repurchase | Modern Healthcare
Big stock buyback: Allergen plans $10 b share repurchase - The Financial Express
Teva: This One Is Difficult (NYSE:TEVA) | Seeking Alpha
J&J prostate cancer drug scores FDA nod; Buffett's investment lifts Teva stocks | S&P Global Market Intelligence
PPT - Health Care: Stock Presentation PowerPoint Presentation, free download - ID:3413855
Hertz Plans $2B Share Repurchase Program
TEVA - Analyst Reports
Mergers Acquisitions Alliances in Emerging Markets Dr Brian
4 Healthcare Stock Stories Demanding Investor Focus
Institutions Have Been Holding Back, but Teva Pharmaceutical Industries Limited (NYSE:TEVA) is Beginning to Stabilize
Allergan Reports Fourth Quarter and Full-Year 2018 Financial Results | AbbVie News Center
Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and Election of Early Settlement
Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and Election of Early Settlement | Business Wire
TEVA Annual Report 2014 | PDF | Food And Drug Administration | Dividend
Teva Pharmaceutical Industries Insider Buying and Selling (NYSE:TEVA)
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
Teva, Allergan complete $39 billion generics deal - CDR – Chain Drug Review
A Pharmaceutical Company With a Resilient Portfolio and Solid Pipeline
Teva: This One Is Difficult (NYSE:TEVA) | Seeking Alpha
TXMD Awaits Big Day Next Week, TEVA Faces FDA In Sep., ESPR On Watch
4 Healthcare Stock Stories Demanding Investor Focus
Teva approves $3 billion share buyback - Business - Haaretz.com
No, Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Isn't Doomed | Nasdaq
Interesting TEVA Put And Call Options For January 2021 | Nasdaq
